Wie presentie zaait zal presentie oogsten

__Abstract__ Wat is presentie? Presentie beoefenaren gaan een relatie aan met mensen die zorg en steun nodig hebben. Het draait in presentie om attentie en aandacht. Zorgorganisaties ontberen presentie, zo leren we wanneer wij in het ziekenhuis of verpleeghuis terecht komen. De presentietheorie (Baart, 2004) is een kritische reflectie hierop, de kritiek van de distantiëring. Distantiëring is gedrag dat tegenovergesteld is aan presentie. Hoe kunnen we de disbalans tussen afstand en nabijheid in de zorg herstellen

Results of the Cooperative Uniform Soybean Tests, 1948 Part I. North Central States

United States Department of Agriculture, Agricultural Research Administration; Bureau of Plant Industry, Soils, and Agricultural Engineering, Division of Forage Crops and Diseases Cooperating with State Agricultural Experiment Station

Results of the Cooperative Uniform Soybean Tests, 1947 Part I. North Central States

United States Department of Agriculture, Agricultural Research Administration; Bureau of Plant Industry, Soils, and Agricultural Engineering, Division of Forage Crops and Diseases Cooperating with State Agricultural Experiment Station

Results of the Cooperative Uniform Soybean Tests, 1946 Part I. North Central States

United States Department of Agriculture, Agricultural Research Administration; Bureau of Plant Industry, Soils, and Agricultural Engineering, Division of Forage Crops and Diseases Cooperating with State Agricultural Experiment Station

Results of the Cooperative Uniform Soybean Tests, 1945. Part I. North Central States

United States Department of Agriculture Agricultural Research Administration Bureau of Plant Industry, Soils, and Agricultural Engineering, Division of Forage Crops and Diseases Cooperating with State Agricultural Experiment Station

Results of the Cooperative Uniform Soybean Tests Part I. North Central States 1949

United States Department of Agriculture, Agricultural Research Administration; Bureau of Plant Industry, Soils, and Agricultural Engineering, Division of Forage Crops and Diseases Cooperating with State Agricultural Experiment Station

IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia

Prognostic index for survival estimation by clinical-demographic variables were previously proposed in chronic lymphocytic leukemia (CLL) patients. Our objective was to test in a large retrospective cohort of CLL patients the prognostic power of biological and clinical-demographic variable in a comprehensive multivariate model. A new prognostic index was proposed

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Background: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. Methods: We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0–1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0–2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4–6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. Findings: Of 249 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THAWS, and ECASS-4. The four trials provided individual patient data for 843 individuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care. A favourable outcome occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among controls (adjusted odds ratio [OR] 1·49 [95% CI 1·10–2·03]; p=0·011), with low heterogeneity across studies (I2=27%). Alteplase was associated with a significant shift towards better functional outcome (adjusted common OR 1·38 [95% CI 1·05–1·80]; p=0·019), and a higher odds of independent outcome (adjusted OR 1·50 [1·06–2·12]; p=0·022). In the alteplase group, 90 (21%) patients were severely disabled or died (mRS score 4–6), compared with 102 (25%) patients in the control group (adjusted OR 0·76 [0·52–1·11]; p=0·15). 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls (adjusted OR 2·06 [1·03–4·09]; p=0·040). The prevalence of symptomatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR 5·58 [1·22–25·50]; p=0·024). Interpretation: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. Funding: None